Introduction {#s1}
============

Arterial blood vessel dilation is mediated, in part, through production of the endogenous endothelial vasodilator molecule, nitric oxide (NO). NO signals by binding to ferrous heme iron in soluble guanylyl cyclase (sGC) in vascular smooth muscle cells (VSMC) to catalyze the intracellular conversion of guanosine 5′-triphosphate to the second messenger molecule cyclic guanosine 3′,5′-monophosphate (cGMP) ([@B1]). Increased cGMP, in turn, activates protein kinase G, leading to vascular smooth muscle relaxation needed to govern tissue perfusion and blood pressure ([@B22]). Indeed, several prior studies conducted in spontaneous hypertensive rats showed sGC mRNA and protein expression to be downregulated and associated with impaired NO-dependent vasodilation ([@B35]; [@B19]). Moreover, smooth muscle cell--specific inducible knockout of sGC *β* in mice results in hypertension, suggesting sGC expression in smooth muscle cells is critical for modulating vascular tone ([@B16]). Genome-wide association studies of single nucleotide polymorphisms also identified genetic variants within the sGC genes *GUCY1A3* and *GUCY1B3* as being associated with a high risk for cardiovascular disease ([@B7]; [@B44]; [@B39]). Of translational importance, small-molecule sGC modulators have been developed for clinical use to restore disease-associated loss of sGC activity and cGMP production to varying degrees of success ([@B48]; [@B40]; [@B10]; [@B25]; [@B27]). For example, riociguat (BAY 63-2521), a heme-dependent sGC stimulator, has been recently approved for treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension ([@B13]). Additionally, cinaciguat (BAY 58-2667), an NO-independent sGC activator, increases cGMP when sGC heme is oxidized or resides in the heme-deficient state ([@B41]), but further studies were halted with BAY 58-2667 after it showed risk for hypotension in a phase IIb clinical trial for treatment of acute heart failure syndrome ([@B12]). Importantly, the clinical efficacy of these sGC modulators is dependent on adequate sGC protein expression.

While the NO-sGC-cGMP pathway continues to be extensively studied, there are a limited number of studies that have identified the mechanisms regulating sGC transcription. Prior work has shown interacting partners with sGC transcripts---namely, human antigen R, which stabilizes the sGC mRNA ([@B21], [@B20]), and miR-34c-5p and ARE/poly(U)-binding/degradation factor 1 (AUF1), which destabilize and promote the degradation of sGC transcripts ([@B31]; [@B47]). Furthermore, CCAAT-binding factor deletion significantly blunts production of sGC mRNA expression in a neuroblastoma cell line ([@B38]). However, beyond these studies, our knowledge of the transcription factor(s) responsible for the constitutive expression of sGC, particularly within VSMCs, remains elusive.

The Forkhead box subclass O (FoxO) family of transcription factors---namely, FoxO1, FoxO3, and FoxO4---are the predominant isoforms in VSMCs ([@B36]). Recent studies have identified the importance of this family of transcription factors in the vasculature, including their role in the promotion of angiogenesis ([@B11]; [@B32]), inhibition of endothelial NO production ([@B32]; [@B45]), prevention of pulmonary hypertension ([@B37]), and maintenance of pluripotency in a variety of different cell types ([@B24]; [@B49]; [@B43]). Additionally, an important observation in the field has established that aging decreases the expression and capacity for FoxO signaling ([@B30]; [@B17]; [@B14]; [@B18]; [@B36]) and has also been shown to decrease the expression of sGC within the vasculature ([@B19]; [@B15]; [@B42]).

However, a link connecting the sGC-cGMP and FoxO pathways has yet to be described. Therefore, with the use of in silico prediction analysis and a previously characterized FoxO inhibitor compound, AS1842856 \[International Union of Pure and Applied Chemistry name: 5-amino-7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid\] ([@B28]), we sought to determine if the FoxO transcription factor family regulates sGC transcription. Herein, we provide evidence that inhibition of FoxO transcription factors results in significant downregulation of sGC transcript and protein, decreased cGMP production, and impaired NO-induced vasodilation, implicating FoxO transcription factors as a major regulator of sGC transcription.

Materials and Methods {#s2}
=====================

 {#s3}

### Cell Culture and Drug Treatment. {#s4}

Rat aortic smooth muscle cells (RASMCs; Lonza) were cultured as previously described ([@B33]). In brief, RASMCs were cultured at 37°C in Lonza Smooth Muscle Growth Medium-2 with SmGm-2 SingleQuot kit (Lonza) supplementation. Cells were passaged using Gibco Trypsin/EDTA up to passage 12. For treatment, FoxO inhibitor AS1842856 (Cayman) was dissolved in DMSO at 10 mM stock concentration and diluted in DMSO for further experiments. Control and treatment DMSO concentration was 0.1% of the total volume for treatment periods.

### Quantitative Reverse-Transcription Polymerase Chain Reaction. {#s5}

RASMCs were cultured in six-well dishes until confluent and lysed in TRIzol reagent (Thermo Fisher). RNA was isolated from lysates according to the RNA purification protocol from the Direct-zol RNA miniprep plus kit (Zymo). Isolated RNA was reverse transcribed to cDNA using SuperScript III First Strand Synthesis System (Thermo Fisher). Quantitative polymerase chain reaction (PCR) was performed using PowerUp SyBr Green Master Mix (Thermo Fisher); 1 *µ*M target primer ([Supplemental Table 1](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.115386/-/DC1)) was mixed; and 40 PCR cycles with 95°C melting temperature, 58°C annealing temperature, and 72°C extension temperature were performed in a QuantStudio 5 Real-Time PCR System (Thermo Fisher).

### Western Blot. {#s6}

RASMCs were lysed in ice-cold 1× cell lysis buffer (Cell Signaling) containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na~2~EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM *β*-glycerophosphate, 1 mM Na~3~VO~4~, and 1 *µ*g/ml leupeptin supplemented with additional protease and phosphatase inhibitors (Sigma-Aldrich). Protein lysate concentrations were quantified using a standard bicinchoninic acid kit (Thermo Fisher). Laemmli buffer was added for a final concentration containing 31.5 mM Tris-HCl (pH 6.8), 10% glycerol, 1% SDS, and 0.005% Bromophenol Blue sodium salt. Lysates were boiled and subjected to electrophoresis on 4%--12% BisTris polyacrylamide gels (Life Technologies). Proteins were transferred to nitrocellulose membrane and blocked for 1 hour at room temperature with 1% bovine serum albumin (BSA) in PBS. Membranes were rocked overnight with primary antibodies ([Supplemental Table 2](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.115386/-/DC1)) diluted in 1% BSA in 0.1% Tween-20 in PBS (PBST) at 4°C. Membranes were washed and incubated with secondary antibodies from LI-COR ([Supplemental Table 2](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.115386/-/DC1)) diluted in 1% BSA in PBST for 1 hour at room temperature followed by washing with PBST. Visualization and analyses were completed utilizing a LI-COR Odyssey Imager and Image Studio Software.

### cGMP ELISA. {#s7}

Confluent RASMCs were cultured in 12-well dishes and pretreated with 10 *µ*M sildenafil (Sigma-Aldrich) for 45 minutes and then stimulated with the NO donor, diethylammonium (Z)-1-(*N*,*N*-diethylamino)diazen-1-ium-1,2-diolate (DEA NONOate; Cayman), for 15 minutes. Baseline measurements were performed after 45-minute treatment with 10 *μ*M sildenafil. Cell samples were lysed in 125 *µ*l of ice-cold 1× cell lysis buffer (Cell Signaling) supplemented with protease and phosphatase inhibitors (Sigma-Aldrich). cGMP production was determined via enzyme-linked immunosorbent assay (ELISA; Cell Signaling). Ten microliters of sample (approximately 5--10 *µ*g of protein) was added to each well and diluted with additional lysis buffer, and exact protein concentration of each sample was quantified using a standard BCA protein assay kit (Thermo Fisher). ELISAs were performed hereafter according to the manufacturer's protocol.

### Immunofluorescence Staining. {#s8}

Twelve-week-old C57BL/6J mice (Jackson Laboratories) were sacrificed via CO~2~ asphyxiation. Thoracic aortas were excised and placed in 4% paraformaldehyde solution for 24 hours, followed by 24 hours in 30% sucrose in PBS. Tissues were then frozen in optimum cutting temperature compound fixative (Tissue-Tek) via liquid nitrogen and cryosectioned at 8-*µ*M thickness with three sections/slide using an FSE Cryostat Microtome slicer (Thermo Scientific). Slides were permeabilized with −20°C acetone for 10 minutes, air dried for 10 minutes, washed thrice for 5 minutes each in PBS, and then blocked with PBS + 0.25% Triton X-100 + 10% horse serum + 1% fish skin gelatin (blocking buffer) for 1 hour. Slides were incubated with rabbit anti-sGC *β* primary antibody and anti-ACTA2 AlexaFluor 488 conjugated primary antibody ([Supplemental Table 2](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.115386/-/DC1)) diluted in blocking buffer (40-*µ*l/section) and placed overnight at 4°C in a darkened humidity chamber. Slides were then washed twice for 5 minutes in 1x PBST, incubated with donkey anti-rabbit AlexaFluor 594 antibody for 1 hour at room temperature in a darkened humidity chamber ([Supplemental Table 2](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.115386/-/DC1)), then washed twice for 5 minutes in 1x PBST. Coverslips were then mounted onto microscope slides using Duolink mounting medium containing 4′,6-diamidino-2-phenylindole, dihydrochloride (DAPI). Aortas were imaged using an Olympus FluoView 1000 confocal microscope. Fluorescence semiquantitation was calculated by quantifying the fluorescent signal from each respective channel relative to the area of aortic tissue imaged via ImageJ software (National Institutes of Health).

### Treatment of Aortic Rings and Myography. {#s9}

The following treatment method was performed as previously described ([@B34]). In brief, isolated murine thoracic aortas were isolated from mice and incubated with 10 *µ*M FoxO inhibitor for 48 hours in one part Lonza Smooth Muscle Growth Medium-2 supplemented with SmGM-2 SingleQuot kit to nine parts unsupplemented Lonza Smooth Muscle Growth Medium-2. Following treatment, aortas were cut into 2-mm rings before being placed on a two-pin myograph (Danish Myo Technology). Aortic rings were then incubated in a physiologic salt solution (PSS) for 30 minutes of rest, after which 500-mg tension was applied to the vessels. Vessel viability was tested using potassium physiologic salt solution for 15 minutes, followed by a triplicate of PSS washes and a 60-minute resting period. Cumulative concentration responses to phenylephrine (10^−9^--10^−5^) and sodium nitroprusside (SNP; 10^−9^--10^−4^) determined vessel contractility and relaxation responses, respectively. Finally, relaxation percentage was determined by normalizing cumulative SNP relaxation to maximal contraction at 10^−5^ M phenylephrine and maximal dilation at 10^−4^ M SNP in Ca^2+^-free PSS.

### Statistics. {#s10}

TRANSFAC analysis software was used to predict FoxO binding sites on sGC promoter DNA utilizing settings to include the minimum number of false positives ([Fig. 1](#F1){ref-type="fig"}). For drug-response and time-course cell culture experiments, Student's *t* test was used to determine significance in [Figs. 5, E--G](#F5){ref-type="fig"} and [6A](#F6){ref-type="fig"} and [Supplemental Fig. 1](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.115386/-/DC1) using GraphPad Prism version 7.03 software, and a one-way analysis of variance (ANOVA) was used to determine significance in [Figs. 2, B, C, E, and F](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}, and [4, A, B, D, and E](#F4){ref-type="fig"} and [Supplemental Fig. 2, A--F](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.115386/-/DC1) using GraphPad Prism version 7.03 software. A two-way ANOVA test for [Fig. 6B](#F6){ref-type="fig"} was performed for each data point to determine significance using GraphPad Prism version 7.03 software. Calculated *P* values represent a significant difference from the control group, error bars represent the S.D., and symbols for confidence are represented by the following: \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, and \*\*\*\**P* \< 0.0001.

![In silico analysis of human sGC promoter. Transcription factor (TF) binding site analysis of human sGC *α* (A) and sGC *β* (B) promoter sequence showed predicted FoxO transcription factor binding sites for 2200-bp promoter fragments flanking the sGC transcription start sites. Numbers indicate distance from transcription start site (TSS). Arrows facing right indicate binding sites on the positive (+) DNA strand; arrows facing left indicate binding sites on the negative (−) DNA strand.](mol.118.115386f1){#F1}

![Treatment of RASMCs with FoxO inhibitor drug AS1842856 shows concentration-dependent decrease in sGC mRNA and protein expression. AS1842856 FoxO inhibitor drug structure (A) and effect on sGC *α* mRNA expression (B) or sGC *β* mRNA expression (C) following 48-hour drug treatment. (D) Western blot and quantification of 48-hour treatment with FoxO inhibitor on sGC *α* protein expression (E) and sGC *β* protein expression (F). *n* = 3 for all samples. One-way ANOVA test was used for determination of significance. \*\*\**P* \< 0.001; \*\*\*\**P* \< 0.0001. Error bars represent S.D.](mol.118.115386f2){#F2}

![Treatment of RASMCs with FoxO inhibitor drug AS1842856 shows concentration-dependent decrease in canonical FoxO targets with compensatory increase in FoxO3 and FoxO4 mRNA expression. Quantitative reverse-transcription PCR from RASMCs treated with FoxO inhibitor. Response for 48-hour FoxO inhibitor treatment measuring FoxO1 (A), FoxO3 (B), FoxO4 (C), Gadd45*α* (D), or glucose-6-phosphatase (G6Pase) (E) mRNA expression. *n* = 3 for all samples. One-way ANOVA test was used for determination of significance. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001; \*\*\*\**P* \< 0.0001. Error bars represent S.D.](mol.118.115386f3){#F3}

![Treatment of RASMCs with FoxO inhibitor drug AS1842856 shows decrease in sGC mRNA, and protein expression occurs rapidly. Quantitative reverse-transcription PCR of 1 *μ*M FoxO inhibitor treatment of 12, 24, and 48 hours on sGC *α* mRNA expression (A) or sGC *β* mRNA expression (B). (C) Western blot and quantification of 1 *μ*M FoxO inhibitor treatment of 12, 24, and 48 hours on sGC *α* protein expression (D) and sGC *β* protein expression (E). *n* = 3 for all samples. One-way ANOVA test was used for determination of significance. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001; \*\*\*\**P* \< 0.0001. Error bars represent S.D.](mol.118.115386f4){#F4}

Results {#s11}
=======

We began our study by analyzing the promoters for both sGC *α* and *β* subunits for potential transcription factor binding sites. TRANSFAC analysis software ([@B9]) was used to evaluate the human sGC promoter using the GRCh38/hg38 reference genome ([@B26]), and 158 and 91 predicted binding sites were identified on the DNA ±10 kbp flanking the sGC *α* and sGC *β* transcription start sites, respectively. We discovered an abundance of FoxO family transcription factor binding sites clustered around 47 binding regions for sGC *α* and 36 binding regions for sGC *β*. Binding domains for FoxO family proteins in coordination with at least one other transcription factor were clustered around 55 regions for sGC*α* ([Supplemental Table 3](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.115386/-/DC1)) and 10 regions for sGC *β* ([Supplemental Table 4](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.115386/-/DC1)). A fragment of each gene's promoter, 2000 bp upstream and 200 bp downstream of the transcription start site (TSS), was analyzed and showed 25 FoxO binding sites on the sGC *α* promoter ([Fig. 1A](#F1){ref-type="fig"}) and 15 binding sites on the sGC *β* promoter ([Fig. 1B](#F1){ref-type="fig"}). FoxO binding sites on sGC *α* were clustered around four locations---namely, 1900, 1800, 1000, and 100 bp upstream of the TSS. Likewise, the 2200-bp sGC *β* promoter fragment contained three clusters of predicted binding sites 1600, 1500, and 1200 bp upstream of the TSS.

The enrichment of the FoxO transcription factors based upon in silico analyses led us to investigate whether our predictive promoter analysis could be validated. We tested this by treating RASMCs with a FoxO inhibitor drug, AS1842856, which has been shown to inhibit all three FoxO isoforms expressed in VSMCs: FoxO1, FoxO3, and FoxO4 ([@B28]). In 48-hour AS1842856 drug ([Fig. 2A](#F2){ref-type="fig"}) treatment experiments in RASMCs, we observed a stoichiometric loss of sGC *α* ([Fig. 2B](#F2){ref-type="fig"}) and sGC *β* ([Fig. 2C](#F2){ref-type="fig"}) mRNA expression of 90%--95% at concentrations of 1 *µ*M or greater. Over the same treatment period, a loss of 80% in the protein expression of sGC *α* ([Fig. 2, D and E](#F2){ref-type="fig"}) and a 74% decrease in sGC *β* ([Fig. 2, D and F](#F2){ref-type="fig"}) were observed at concentrations of 1 *µ*M or greater. Increasing concentrations of AS1842856 were accompanied by no change in FoxO1 mRNA expression ([Fig. 3A](#F3){ref-type="fig"}), while an increase in FoxO3 ([Fig. 3B](#F3){ref-type="fig"}) and FoxO4 ([Fig. 3C](#F3){ref-type="fig"}) mRNA expression was observed. Classic FoxO transcriptional targets, such as growth arrest and DNA damage inducible *α* (Gadd45*α*) and glucose-6-phosphatase expression, exhibited the same degree of decreased gene expression (greater than 90%) at concentrations of 1 *µ*M or greater ([Fig. 3, D and E](#F3){ref-type="fig"}). These drug experiments showed that inhibition of FoxO transcriptional activity was commensurate with a loss of sGC expression, suggesting that the FoxO family plays a regulatory role in sGC gene expression. Additionally, measurement of the gene expression of cyclic nucleotide--generating enzymes adenylate cyclase (ADCY) and particulate guanylyl cyclase (pGC) showed that FoxO inhibition did not have a significant dampening effect on their expression. In fact, FoxO inhibition caused increased gene expression of ADCY1 and pGC1 with no significant changes in gene expression of ADCY3 or pGC2 ([Supplemental Fig. 1](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.115386/-/DC1)).

FoxO temporal activity on sGC expression was then assessed using cultured RASMCs treated with 1 *µ*M FoxO inhibitor. We observed that sGC *α* ([Fig. 4A](#F4){ref-type="fig"}; [Supplemental Fig. 2A](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.115386/-/DC1)) and sGC *β* ([Fig. 4B](#F4){ref-type="fig"}; [Supplemental Fig. 2B](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.115386/-/DC1)) mRNA expression significantly decreased after initial inhibitor administration and continued to decline with increased drug exposure time. Moreover, suppression of sGC mRNA was observed throughout the treatment period, reaching 80%--90% reduction by 48 hours ([Fig. 4, A and B](#F4){ref-type="fig"}). As with the drug-response experiment, the loss of sGC *α* and *β* protein expression over time ([Fig. 4, C--E](#F4){ref-type="fig"}) mirrored the observations in mRNA. sGC protein expression was marginally affected during the first few hours after FoxO inhibition, diminished by 32% loss of sGC *α* and 40% loss of sGC *β* within 6 hours ([Supplemental Fig. 2, D--F](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.115386/-/DC1)), while significant losses in gene expression of sGC *α* ([Supplemental Fig. 2A](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.115386/-/DC1)), sGC *β* ([Supplemental Fig. 2B](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.115386/-/DC1)), and glucose-6-phosphatase ([Supplemental Fig. 2C](http://molpharm.aspetjournals.org/lookup/suppl/doi:10.1124/mol.118.115386/-/DC1)) were observed within 3 hours of drug treatment. This trend was also observed in the longer time-course experiments, wherein it reached maximal loss of 78% sGC *α* and 76% sGC *β* by the end of the 48-hour treatment period ([Fig. 4, D and E](#F4){ref-type="fig"}). Combined, these experiments provide evidence that the loss of sGC expression in cultured RASMCs via inhibition of FoxO transcriptional activity occurs rapidly and remains impaired throughout a 48-hour treatment period.

We then assessed the impact of FoxO inhibition on sGC protein expression within isolated blood vessels. Mouse thoracic aortas were isolated and treated with 10 *µ*M FoxO inhibitor drug for 48 hours and then immunostained for sGC *β*, smooth muscle *α* actin (ACTA2), and nuclei (DAPI). A higher concentration compared with culture experiments was necessary for loss of sGC expression, as studies have shown that sGC protein is highly stable in vivo ([@B16]). We chose to treat ex vivo tissue to circumvent the extensive mechanisms to stabilize sGC protein in vivo. FoxO inhibitor treatment decreased sGC *β* protein expression by 48% ([Fig. 5, A, A′, and E](#F5){ref-type="fig"}) but had no significant effect on the expression of ACTA2 ([Fig. 5, B, B′, and F](#F5){ref-type="fig"}) or on the density of nuclei staining (DAPI) within these isolated blood vessels ([Fig. 5, C, C′, and G](#F5){ref-type="fig"}). Taken together, these data show that inhibition of FoxO activity in ex vivo tissue significantly lowers sGC expression, consistent with our previous studies in RASMCs ([Fig. 5, D and D′](#F5){ref-type="fig"}).

![sGC expression in ex vivo murine aortas treated with FoxO inhibitor was decreased. Representative staining for ex vivo murine aortas treated with 10 *μ*M FoxO inhibitor for 48 hours showing sGC *β* protein (A and A′), ACTA2 (B and B′), DAPI (C and C′), and merged channels (D and D′). Quantification of immunostaining for sGC *β* protein (E), ACTA2 protein (F), or DAPI staining (G). *n* = 3 animals. Student's unpaired *t* test was used for determination of significance. \**P* \< 0.05. Error bars represent S.D.](mol.118.115386f5){#F5}

Next, the extent to which FoxO inhibition impacts sGC signaling function was examined by measuring RASMC cGMP production and isolated aorta vessel relaxation. Cultured RASMC experiments showed that after 1 *µ*M FoxO inhibitor treatment of 48-hours, cGMP production was reduced 85%--90% after stimulation with 0.5--1 *µ*M of NO donor DEA NONOate ([Fig. 6A](#F6){ref-type="fig"}). Similarly, ex vivo vessel myography studies on isolated murine aortas treated with 10 *µ*M FoxO inhibitor for 48 hours showed impaired vasodilation in response to concentrations of the NO donor SNP greater than 100 nM ([Fig. 6B](#F6){ref-type="fig"}). Collectively, these data suggest that the loss of sGC expression following FoxO inhibition results in a corresponding loss of NO-dependent, sGC-mediated cGMP production and vasoreactivity.

![NO-dependent signaling in RASMCs and murine aortas is blunted after treatment with AS1842856. (A) cGMP produced by cultured RASMCs treated with AS1842856 and stimulated with NO donor DEA NONOate (*n* = 4). Student's unpaired *t* test was used for determination of significance. (B) Ex vivo murine aortic vessels treated with 10 *μ*M FoxO inhibitor or DMSO for 48 hours and dilated using the NO donor SNP (*n* = 5). Two-way ANOVA was used to determine significance. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001; \*\*\*\**P* \< 0.0001. Error bars represent S.D.](mol.118.115386f6){#F6}

Discussion {#s12}
==========

sGC is crucial for NO-dependent relaxation to maintain cardiovascular health. To date, few studies have investigated the transcriptional regulation of sGC, and none have identified the transcription factors responsible for the constitutive expression of sGC within the vasculature. Prior work showed the CCAAT-binding factor regulates sGC gene expression within a neuroblastoma cell line ([@B38]). However, no such regulation of sGC was observed in VSMCs, which prompted us to search for other transcription factors capable of initiating sGC transcription. One candidate family, the FoxO family of transcription factors, is known to regulate the development of new blood vessels and has been implicated in the prevention of pulmonary arterial hypertension ([@B11]; [@B37]; [@B6]). Our predictive analysis of the human *GUCY1A3* and *GUCY1B3* promoters showed that a plethora of potential FoxO binding sites are found along the upstream genetic regions of both sGC subunits. These findings inspired further exploration of the impact of FoxO proteins on the expression and downstream function of sGC.

In this study, we inhibited FoxO transcriptional activity using a pan-FoxO inhibitor (AS1842856) and observed significant decreases in the gene expression of sGC and well established targets of FoxO proteins. The decrease in sGC mRNA transcription demonstrated a stoichiometric decrease in both sGC *α* and sGC *β* gene expression. This inhibition rapidly attenuated sGC gene expression and signified that the decrease in expression of one gene matched the expression of the other. Proportionate sGC *α* and sGC *β* protein expression is necessary for optimal enzymatic activity of the obligate heterodimeric protein. Therefore, a symmetrical decrease in both sGC *α* and sGC *β* mRNA and protein suggests dual *α* and *β* regulation by FoxO transcriptional activity. Alternatively, it is possible that mechanisms which destabilize or stabilize sGC mRNA have the capability to alter sGC expression. For example, increases in the mRNA destabilizer AUF1 or loss of an sGC mRNA chaperone, human antigen R, could contribute to the observed loss of sGC mRNA ([@B31]; [@B21], [@B20]), but exploration of these hypotheses would require further investigation.

In a similar manner to the observations in sGC mRNA expression, FoxO inhibitor treatment decreased sGC *α* and *β* protein expression in cultured RASMCs commensurate with the swift concentration-dependent loss of sGC mRNA expression. Moreover, FoxO inhibition in mouse aortas caused a loss of sGC *β* protein expression and vascular reactivity. This likely suggests that the loss of protein expression and downstream activity occurs as a direct result of the loss of sGC mRNA and not through post-translational regulatory mechanisms. Signaling molecules identified to have effects on sGC protein expression, such as transforming growth factor *β* in the developing lung, have decreased expression of sGC *α*~1~ protein; however, no change was observed on the expression of sGC mRNA in response to hypoxia-induced transforming growth factor *β* expression ([@B2]). Furthermore, the chaperone-dependent E3-ligase protein, C terminus of heat shock cognate 70-interacting protein (CHIP), which is responsible for degradation of sGC protein, also targets the FoxO proteins for proteasomal degradation ([@B46]; [@B23]). Previous studies also indicated that the half-life of sGC *β* in cultured cells due to CHIP breakdown is roughly 7 hours ([@B46]), which was consistent with the observed rate of sGC protein loss after our FoxO inhibition experiments and acted as the reasoning for longer drug treatment to observe a loss of protein expression and functional responses in the vasculature. As a result, FoxO inhibitor treatment alone on CHIP activity would presumably affect both sGC and the FoxO proteins, while mRNA expression would not be directly affected. In response to the effects on sGC mRNA expression, the observed loss of sGC protein expression was due to the lack of sGC transcript production. Additionally, FoxO inhibition caused a 90% reduction of cGMP production by sGC, which presumably led to the observed increase in gene expression of pGC1 as a compensatory mechanism. Despite this increase in pGC1 gene expression, the predominant method of cGMP production in smooth muscle is derived from sGC ([@B16]); thus, it is unclear whether this compensatory increase would rescue lost function due to impaired NO-dependent cGMP signaling. This effect on sGC protein expression in both culture and ex vivo tissue manifests in a loss of cGMP production and subsequent blunting of NO-dependent vasodilation.

We hypothesize that multiple FoxO proteins play a role in the physiologic transcription of sGC mRNA due to partial redundancy of the transcription factors as well as a nonselective effect of the inhibitor drug on all FoxO family members. While we cannot rule out off-target effects of the FoxO inhibitor, our data thus far do not suggest an off-target effect is responsible for the regulation of sGC that we observed. Based upon our pharmacological data and that of [@B28] when characterizing this FoxO inhibitor drug, disparate effects on transcriptional activity of each of the FoxO proteins are observed after treatment. Pharmacodynamic studies indicate that FoxO1 is 70% inhibited, FoxO4 is 20% inhibited, and FoxO3 is 3% inhibited at a treatment concentration of 100 nM ([@B28]). A recent study also used several in silico modeling methods to predict a −6.3-kcal/mol binding energy of AS1842856 to FoxO1 and identified 10 amino acids in the transactivation domain which constitute drug-protein hydrogen bonding and hydrophobic interactions ([@B5]). These studies suggest that AS1842856 is specific for the transactivation domain of FoxO1, which governs the activity of the transcription factor after binding the target DNA sequences. Additionally, the lower affinity for AS1842856 to elicit FoxO3 and FoxO4 inhibition likely explains the necessity for higher drug concentration to induce the loss of sGC transcription in both cultured cells and isolated tissue. Our experiments also showed that FoxO3 and FoxO4 mRNA expression are elevated in response to drug treatment. These differential effects of the inhibitor drug on each of the isoforms suggest a complicated mechanism with multiple contributing factors in the compensatory expression of FoxO3 and FoxO4. Promoter analyses also showed that the FoxO transcription factors share affinity for the same conserved "TTGTTTAC" DNA motifs, which is supported by previous research ([@B3]; [@B29]; [@B4]). This detail may indicate that loss of one transcription factor alone may not be sufficient to achieve the observed knock down of sGC expression in this study. Further investigation is required to elucidate the contributions of each FoxO protein in the transcription of sGC.

Many therapies available today, which include nitrovasodilator compounds that increase the bioavailability of NO ([@B1]), and drugs that target sGC directly ([@B48]; [@B8]; [@B12]; [@B13]) both promote second messenger cGMP signaling to improve cardiovascular health. Deficits in sGC transcription can eliminate the protein target of current therapeutic drugs, rendering many of them ineffective. Discovery of FoxO transcription factors as key regulators of the NO-sGC-cGMP signaling pathway within VSMCs also presents a potential contraindication that should be monitored when considering FoxO inhibitor drugs, such as AS1842856. Anomalies in blood pressure and other cardiovascular characteristics will be important biomarkers in future drug development studies involving the FoxO proteins. Taken together, the identification of the key transcription factors responsible for production of sGC mRNA is a vital component to understanding how cardiovascular homeostasis is regulated.

In summary, our study is the first to identify a family of transcription factors---namely, the FoxO family---capable of regulating sGC expression in vascular smooth muscle. This reveals a pivotal new role for the FoxO transcription factors in modulating vascular tone, and our next studies will investigate the specific role of each FoxO transcription factor in the regulation of sGC transcription. The discovery of the FoxO family as transcriptional regulators for sGC not only provides an alternative therapeutic approach for blood pressure control but also reveals a potentially novel mechanism that may impact sGC-related cardiovascular diseases.
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ADCY

:   adenylate cyclase

BSA

:   bovine serum albumin

cGMP

:   cyclic guanosine 3′,5′-monophosphate

CHIP

:   C terminus of heat shock cognate 70-interacting protein

DAPI

:   4′,6-diamidino-2-phenylindole, dihydrochloride

FoxO

:   Forkhead box subclass O

NO

:   nitric oxide

PBST

:   0.1% Tween-20 in PBS

PCR

:   polymerase chain reaction

pGC

:   particulate guanylyl cyclase

PSS

:   physiologic salt solution

RASMC

:   rat aortic smooth muscle cell

sGC

:   soluble guanylyl cyclase

SNP

:   sodium nitroprusside

TSS

:   transcription start site

VSMC

:   vascular smooth muscle cell
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